IL17A and psoriasis: As the immunologic pathophysiology of psoriasis is being more clearly elucidated, biologics, such as tumor necrosis factor (TNF)-α inhibitors, interleukin (IL)-12/23 inhibitors, and IL-17 inhibitors, have recently emerged as main treatment options for psoriasis3–5.